Denmark

Symphogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Servier Completes the Acquisition of Symphogen

Lead Product(s): Sym021

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Laboratoires Servier

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 04, 2020

Details:

As a result of this acquisition Symphogen becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.

Symphogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline

Lead Product(s): Sym021

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Servier Canada

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition April 03, 2020

Details:

Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.

Scandion Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells

Lead Product(s): SCO-101

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 25, 2020

Details:

Based on modelling of preclinical data with docetaxel resistant cancer cells, Scandion Oncology has published that SCO-101 significantly increases the potency of docetaxel.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Symphogen

Servier Completes the Acquisition of Symphogen

Symphogen

Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline

Scandion Oncology

SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells